Research Reports Initiation on Biotech Stocks -- Heat Biologics, Geron, Seattle Genetics, and Grifols

03:03 EDT 19 Oct 2016 | PR Newswire

NEW YORK, October 19, 2016 /PRNewswire/ --

Today, takes note of the following Biotechnology companies: Heat Biologics Inc. (NASDAQ: HTBX), Geron Corp. (NASDAQ: GERN), Seattle Genetics Inc. (NASDAQ: SGEN), and Grifols S.A. (NASDAQ: GRFS). Last week, the share price of iShares Nasdaq Biotechnology ETF (IBB) dropped to significant lows, down more than 6% between Tuesday and Thursday. According to an article on Investopedia, the ETF was trading below $270 per share on Thursday, October 13, 2016, compared to Monday's closing price of $288 a share. Learn more about these stocks by downloading their free report at:

Heat Biologics  

Durham, North Carolina-based Heat Biologics Inc.'s stock finished Tuesday's session 0.85% lower at $1.17 with a total trading volume of 283,586 shares. The Company's shares have advanced 17.00% in the previous three months. The stock is trading 1.87% below its 200-day moving average. Additionally, shares of Heat Biologics, which focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the US, have a Relative Strength Index (RSI) of 35.84.

On October 13th, 2016, Heat Biologics announced that it continues to remain on track to report topline data this quarter from its Phase 2 trials evaluating HS-410 and HS-110 for the treatment of non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC), respectively, as well as its Phase 1b trial evaluating HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, Opdivo®, for the treatment of NSCLC. The free research report on HTBX is available at:


On Tuesday, shares in Menlo Park, California-based Geron Corp. recorded a trading volume of 1.54 million shares. The stock ended the session 2.88% higher at $2.14. The Company's shares have advanced 7.00% in the last one month. The stock is trading 13.42% below its 50-day moving average. Moreover, shares of Geron, which focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies, have an RSI of 41.55.

On September 12th, 2016, Geron provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of the telomerase inhibitor imetelstat. Planned internal reviews of initial data from both trials have been completed by Janssen, and both trials are continuing in order to evaluate additional and more mature data. The complimentary report on GERN can be downloaded at:

Seattle Genetics  

Shares in Bothell, Washington headquartered Seattle Genetics Inc. closed the day 1.18% higher at $50.73. The stock recorded a trading volume of 723,950 shares. The Company's shares have gained 16.89% in the previous three months and 13.03% on an YTD basis. The stock is trading 0.58% above its 50-day moving average and 25.09% above its 200-day moving average. Additionally, shares of Seattle Genetics, which develops and commercializes targeted therapies for the treatment of cancer worldwide, have an RSI of 43.14.

On October 07th, 2016, Seattle Genetics and Agensys, an affiliate of Astellas, presented updated clinical data for enfortumab vedotin (ASG-22ME) and ASG-15ME at the European Society for Medical Oncology (ESMO). Enfortumab vedotin and ASG-15ME are investigational antibody-drug conjugates (ADCs) that target the cell surface proteins Nectin-4 and SLITRK6, respectively. The clinical data for both agents continue to demonstrate overall response rates in patients with previously treated metastatic urothelial cancer, including those with prior checkpoint inhibitors. Safety and recommended phase 2 doses were also presented for both programs. While both phase 1 studies will continue to enroll patients, the companies plan to advance enfortumab vedotin and discuss next steps with regulatory agencies.

On October 10th, 2016, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $55 a share to $62 a share. Visit us today and download our complete research report on SGEN for free at:


At the close, shares in Barcelona, Spain headquartered Grifols S.A. ended at $15.36, up 1.65%. The stock recorded a trading volume of 791,962 shares, which was above its three months average volume of 755,470 shares. The Company's shares are trading below their 200-day moving average by 2.12%. Furthermore, shares of Grifols, which develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the US, Canada, and internationally, have an RSI of 39.03.

On September 05th, 2016, Grifols announced the opening of its new training center in Dubai. Created to support the company's growing Diagnostic business, the center will offer single and multi-day training courses for laboratory technicians, engineers, and specialists working with the company's broad portfolio of Transfusion Medicine and Clinical Diagnostic instruments, assays, and software. The center will also train attendees on associated best practices in the laboratory. Get free access to your technical report on GRFS at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number:  +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


More From BioPortfolio on "Research Reports Initiation on Biotech Stocks -- Heat Biologics, Geron, Seattle Genetics, and Grifols"

Quick Search

Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...